Compare · LBRX vs NVO
LBRX vs NVO
Side-by-side comparison of LB Pharmaceuticals Inc (LBRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LBRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 234.5x LBRX ($818.1M).
- Over the past year, LBRX is up 55.3% and NVO is down 45.1% - LBRX leads by 100.4 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 6 for LBRX).
- Company
- LB Pharmaceuticals Inc
- Novo Nordisk A/S
- Price
- $28.69+0.49%
- $41.46-3.45%
- Market cap
- $818.1M
- $191.82B
- 1M return
- -9.89%
- -9.44%
- 1Y return
- +55.33%
- -45.05%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 8
- 8
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LBRX
- SEC Form 4 filed by Director Ruffolo Robert R
- SEC Form 4 filed by Director Nussbaum Ran
- SEC Form 4 filed by Director Luse Rebecca
- SEC Form 4 filed by Director Lenz Robert A.
- SEC Form 4 filed by Director Hemrajani Rekha
- SEC Form 4 filed by Director Kane William P Jr
- SEC Form 4 filed by Director Garland J. Scott
- LB Pharmaceuticals to Participate in Upcoming June Investor Events
- Amendment: SEC Form SCHEDULE 13G/A filed by LB Pharmaceuticals Inc
- SEC Form 424B3 filed by LB Pharmaceuticals Inc
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care